WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience
 QUICK SEARCH:   [advanced]


     
-


HOME
  |  
SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, March 22, 2006, 26(12):3169-3181; doi:10.1523/JNEUROSCI.5120-05.2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (37)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yee, B. K.
Right arrow Articles by Boison, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yee, B. K.
Right arrow Articles by Boison, D.

 Previous Article  |  Next Article 

Behavioral/Systems/Cognitive
Disruption of Glycine Transporter 1 Restricted to Forebrain Neurons Is Associated with a Procognitive and Antipsychotic Phenotypic Profile

Benjamin K. Yee,1 Ela Balic,2 Philipp Singer,1 Cornelia Schwerdel,2 Thomas Grampp,2 Laetitia Gabernet,2 Irene Knuesel,1 Dietmar Benke,2 Joram Feldon,1 Hanns Mohler,2,3 and Detlev Boison4

1Laboratory of Behavioral Neurobiology, Swiss Federal Institute of Technology, 8603 Schwerzenbach, Switzerland, 2Institute of Pharmacology and Toxicology, University of Zurich, 8057 Zurich, Switzerland, 3Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology and Collegium Helveticum, 8093 Zurich, Switzerland, and 4R. S. Dow Neurobiology Laboratories, Legacy Research, Portland, Oregon 97232

Correspondence should be addressed to Dr. Detlev Boison, Dow Neurobiology Laboratories, Legacy Research, 1225 Northeast 2nd Avenue, Portland, OR 97232. Email: dboison{at}downeurobiology.org

The NMDA receptor is thought to play a central role in some forms of neuronal plasticity, including the induction of long-term potentiation. NMDA receptor hypofunction can result in mnemonic impairment and has been implicated in the cognitive symptoms of schizophrenia. The activity of NMDA receptors is controlled by its endogenous coagonist glycine, and a local elevation of glycine levels is expected to enhance NMDA receptor function. Here, we achieved this by the generation of a novel mouse line (CamKII{alpha}Cre;Glyt1tm1.2fl/fl) with a neuron and forebrain selective disruption of glycine transporter 1 (GlyT1). The mutation led to a significant reduction of GlyT1 and a corresponding reduction of glycine reuptake in forebrain samples, without affecting NMDA receptor expression. NMDA (but not AMPA) receptor-evoked EPSCs recorded in hippocampal slices of mutant mice were 2.5 times of those recorded in littermate controls, suggesting that neuronal GlyT1 normally assumes a specific role in the regulation of NMDA receptor responses. Concomitantly, the mutants were less responsive to phencyclidine than controls. The mutation enhanced aversive Pavlovian conditioning without affecting spontaneous anxiety-like behavior in the elevated plus maze and augmented a form of attentional learning called latent inhibition in three different experimental paradigms: conditioned freezing, conditioned active avoidance, conditioned taste aversion. The CamKII{alpha}Cre;Glyt1tm1.2fl/fl mouse model thus suggests that augmentation of forebrain neuronal glycine transmission is promnesic and may also offer an effective therapeutic intervention against the cognitive and attentional impairments characteristic of schizophrenia.

Key words: glycine transporter 1; NMDA receptor; conditional knock-out mice; latent inhibition; selective attention; learning; schizophrenia


Received Dec. 1, 2005; revised Jan. 12, 2006; accepted Feb. 6, 2006.

Correspondence should be addressed to Dr. Detlev Boison, Dow Neurobiology Laboratories, Legacy Research, 1225 Northeast 2nd Avenue, Portland, OR 97232. Email: dboison{at}downeurobiology.org




This article has been cited by other articles:


Home page
Schizophr BullHome page
I. Gaisler-Salomon, S. A. Schobel, S. A. Small, and S. Rayport
How High-Resolution Basal-State Functional Imaging Can Guide the Development of New Pharmacotherapies for Schizophrenia
Schizophr Bull, November 1, 2009; 35(6): 1037 - 1044.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Fernandez-Sanchez, J. Martinez-Villarreal, C. Gimenez, and F. Zafra
Constitutive and Regulated Endocytosis of the Glycine Transporter GLYT1b Is Controlled by Ubiquitination
J. Biol. Chem., July 17, 2009; 284(29): 19482 - 19492.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
H. X. Zhang, K. Hyrc, and L. L. Thio
The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine
J. Physiol., July 1, 2009; 587(13): 3207 - 3220.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Mezler, W. Hornberger, R. Mueller, M. Schmidt, W. Amberg, W. Braje, M. Ochse, H. Schoemaker, and B. Behl
Inhibitors of GlyT1 Affect Glycine Transport via Discrete Binding Sites
Mol. Pharmacol., December 1, 2008; 74(6): 1705 - 1715.
[Abstract] [Full Text] [PDF]



-
-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help

-
Copyright 2009 by Society for Neuroscience ONLINE ISSN: 1529-2401
-